New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For FLDM;LLY;OVSC;STEM;LH;PFE;NBS;ACTC;ATHX;PSTI;CYTX From The Last 14 Days
Check below for free stories on FLDM;LLY;OVSC;STEM;LH;PFE;NBS;ACTC;ATHX;PSTI;CYTX the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
July 24, 2014
06:33 EDTLLYEli Lilly reports Q2 EPS 68c, consensus 65c
Reports Q2 revenue $4.94B, consensus $4.9B.
July 23, 2014
15:30 EDTLLYNotable companies reporting before tomorrow's open
Notable companies reporting before tomorrow's market open, with earnings consensus, include Ford (F), consensus 36c; General Motors (GM), consensus 58c; Potash (POT), consensus 46c; Caterpillar (CAT), consensus $1.52; 3M (MMM), consensus $1.91; Union Pacific (UNP), consensus $1.43; Bristol-Myers Squibb (BMY), consensus 44c; Eli Lilly (LLY), consensus 65c; Celgene (CELG), consensus 89c; Precision Castparts (PCP), consensus $3.35; Raytheon (RTN), consensus $1.59; Noble Energy (NBL), consensus 79c; Hershey (HSY), consensus 76c; Southwest Airlines (LUV), consensus 61c; Boston Scientific (BSX), consensus 19c; JetBlue (JBLU), consensus 19c.
14:06 EDTLLYEarnings Preview: Lilly counts on newer drugs to drive revenue
Subscribe for More Information
09:06 EDTSTEMCapital Ventures International reports 6.5% passive stake in StemCells
July 22, 2014
16:18 EDTPFEPuma Biotech now responsible for R&D expenses associated with legacy trials
Subscribe for More Information
July 21, 2014
08:09 EDTLHLabCorp price target raised to $130 from $120 at Maxim
Subscribe for More Information
July 18, 2014
12:04 EDTLHLabCorp pullback a buying opportunity, says Maxim
Subscribe for More Information
11:25 EDTLHPiper awaits notable volume recovery to get more positive on LabCorp
Piper Jaffray views LabCorp's in-line quarter as positive and said restored TRICARE coverage may provide added upside, but the firm would like to see notable lab volume recovery and a pullback in the shares before becoming more positive on the stock. Piper raised its price target on the stock to $99 from $98 and maintains its Neutral rating on LabCorp.
06:43 EDTLHLabCorp raises FY14 adjusted EPS to $6.50-$6.75 from $6.40-$6.70
Subscribe for More Information
06:43 EDTLHLabCorp: Q2 sales increase due to test volume
Total test volume increased 5.3%, while revenue per requisition decreased 2.0% due to test and payer mix. Reports Q2 operating income $246.7M, operating cash flow $207.4M, free cash flow $159M
06:41 EDTLHLabCorp reports Q2 adjusted EPS $1.84, consensus $1.77
Subscribe for More Information
July 17, 2014
09:34 EDTLHLabCorp upgraded to Outperform from Market Perform at William Blair
Subscribe for More Information
08:08 EDTPFEBristol-Myers, Pfizer announce enrollment in Phase IV EMANATE trial for Eliquis
Subscribe for More Information
July 16, 2014
10:36 EDTPFETreasury calls on Congress to halt inversion deals
Subscribe for More Information
09:27 EDTPFEPfizer to acquire InnoPharma for upfront cash payment of $225M
Subscribe for More Information
08:21 EDTLLYEli Lilly reports beta-amyloid imaging results in Alzheimer's Disease
Subscribe for More Information
07:59 EDTPFETreasury Secretary urges Congress to take action on tax inversions
Subscribe for More Information
07:23 EDTNBSRedChip Companies to hold a virtual conference
Subscribe for More Information
07:05 EDTLLYEli Lilly and Immunocore partner to develop cancel therapies
Eli Lilly and Immunocore today announced they have entered into a co-discovery and co-development collaboration to research and potentially develop novel T cell-based cancer therapies. Immunocore will receive an upfront fee of $15M per program for the discovery of novel ImmTACs against jointly-selected cancer targets in order to generate preclinical candidate packages. If Lilly accepts a preclinical candidate package to develop and potentially commercialize, Immunocore will receive an opt-in fee of $10M and will have an option to continue co-development with Lilly on a cost-sharing and profit-sharing basis. If Immunocore does not exercise its option, it will be entitled to potential future significant milestone and royalty payments.
07:04 EDTPFEPfizer says primary endpoint met in Phase 3 study of BeneFIX
Pfizer announced the positive results of a Phase 3 study comparing a prophylaxis regimen of BeneFIX Coagulation Factor IX 100 IU/kg once-weekly to on-demand treatment in people with moderately severe to severe hemophilia B. The top-line results of the study showed that the primary study endpoint was met and hemophilia B patients taking once-weekly BeneFIX showed a statistically significant reduction in the annualized bleeding rate relative to on-demand treatment with BeneFIX. In the study, the median ABR value, a commonly used measure of efficacy for prophylaxis regimens in hemophilia, was 2.0 for the prophylaxis regimen, compared to 33.6 for the on-demand regimen, representing a 94% decrease in bleeding rates. The mean ABR value was 3.6 for the prophylaxis period, compared to 32.9 for the on-demand treatment, which represents a reduction of 89%. Study results also showed that prophylaxis treatment significantly reduced both spontaneous and traumatic ABR compared to on-demand treatment with BeneFIX. In addition to meeting the primary endpoint, the secondary study endpoints showed that none of the 1,254 prophylaxis infusions administered during the study were associated with a less than expected therapeutic effect occurrence, which was defined as a spontaneous bleed occurring within 48 hours of a prophylaxis infusion. These results are preliminary, top-line data and are subject to additional analyses. Complete results from this study will be submitted for presentation at upcoming medical congresses and submitted for publication in a peer-reviewed journal.
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use